To standardize the construction and management of biobanks for allergic diseases in China and promote the deep integration of clinical resources with research needs, the Allergy Prevention and Control Committee of the Chinese Preventive Medicine Association, the Chinese Society of Allergy of the Chinese Medical Association, and the National Clinical Research Center for Respiratory Diseases, among other institutions, jointly led the development of the "Expert consensus on the standardized construction and management of biobanks for allergic diseases (2026 edition)". This consensus was formulated based on the "Guidelines for the Development/Revision of Clinical Practice Guidelines in China (2022 edition)" and the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system, through multidisciplinary expert discussions and Delphi voting. The content covers strategic positioning, standardized collection and processing, ethical and privacy protection, information management and data governance, full-process quality control, biosafety risk prevention, and personnel development. The consensus puts forward 10 recommendations, emphasizes a collaborative mechanism of "co-construction, co-management, and sharing", and provides scientific and actionable practical guidance tailored to China's regional characteristics. It aims to advance the development of precision medicine for allergic diseases and contribute China's expertise to global allergy research.
为规范我国过敏性疾病生物样本库的建设与管理，促进临床资源与科研需求深度融合，中华预防医学会过敏病预防与控制专业委员会、中华医学会变态反应学分会、呼吸系统疾病国家临床医学研究中心等机构联合牵头制订了《过敏性疾病生物样本库规范化建设和管理专家共识（2026版）》。本共识依据《中国制订/修订临床诊疗指南的指导原则（2022版）》及GRADE分级系统，通过多学科专家研讨与德尔菲投票形成。内容涵盖样本库的战略定位、标准化采集与处理、伦理与隐私保护、信息化与数据管理、全流程质量控制、生物安全风险防控及人才队伍建设。共识提出了10条推荐意见，强调“共建、共管、共享”的多中心协作机制，并结合中国地域特点提供科学、可操作的实践指导，旨在推动过敏性疾病精准医学发展，为全球过敏研究贡献中国经验。.